Answer
Recognised severe (grade 3) or life-threatening (grade 4) toxicities with Blincyto (blinatumomab) include cytokine release syndrome, tumour lysis syndrome, neurological toxicity, elevated liver enzymes and other clinically relevant toxicities.
Sources for this answer
- BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §4.2 Posology and method of administration · Version 25Document updated
Sources checked